Abstract
Black Americans are under-represented in cancer clinical trials because of myriad factors. Minority under-representation in clinical trials likely contributes to the disparate cancer outcomes among minorities and the poor. This Commentary, in light of a clinical trial that was prematurely terminated because of poor accrual of black men, discusses strategies to identify and overcome barriers to enrollment for this particularly vulnerable population.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
